source
- Eli Lilly's $7B acquisition of Kelonia highlighted by full-cohort response in in-vivo CAR-T trial for multiple myelomaAt ASCO 2026, Kelonia Therapeutics presented data on its in-vivo CAR-T platform for multiple myeloma. The report covered 18 patients treated with the therapy, all of whom showed encouraging outcom…
- Medicare launches $50/month coverage for Wegovy and Zepbound but withholds cost to taxpayersMedicare announced a temporary “GLP-1 Bridge” program that will allow adults 65 and older to receive the obesity treatments Wegovy and Zepbound for $50 a month beginning July 1. The program runs t…